01—Abstract
Summary
Summary of the 8-K filed December 10, 2025. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (LH) filed a Form 8-K on December 10, 2025 to report that Dr. D.
Gary Gilliland notified the Board of Directors on December 5, 2025 of his decision to retire from the Board, effective December 31, 2025. The filing is disclosed under Item 5.02 (Departure of Directors or Certain Officers) and Item 7.01 (Regulation FD Disclosure). The company issued a press release on December 10, 2025, announcing the retirement, attached as Exhibit 99.1.
The release states that Dr. Gilliland became a director in 2014, served on the Audit Committee and the Quality and Compliance Committee, and has been President and Director Emeritus of the Fred Hutchinson Cancer Research Center since January 2020. Chairman and CEO Adam Schechter credited him with extensive knowledge of oncology and gene therapy and cited more than 10 years of service. Dr. Garheng Kong, lead independent director and chair of the Nominating and Corporate Governance Committee, praised his contributions to strengthening the company.
For investors, this is a routine board transition with no financial results, guidance, or operational changes disclosed in the filing. The filing does not state a successor or any replacement arrangement.
02—Key points
Key Highlights
- Dr. D. Gary Gilliland will retire from the Labcorp Board of Directors effective December 31, 2025, having notified the Board on December 5, 2025.
- Dr. Gilliland joined the Board in 2014 and served on the Audit Committee and the Quality and Compliance Committee.
- He has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center since January 2020.
- Prior roles include inaugural Vice Dean and Vice President for Precision Medicine at the University of Pennsylvania Perelman School of Medicine and Senior Vice President of Merck Research Laboratories and Oncology Franchise Head.
- The announcement was made through a press release dated December 10, 2025, furnished as Exhibit 99.1 under Regulation FD.
- Chairman and CEO Adam Schechter and lead independent director Dr. Garheng Kong publicly praised Dr. Gilliland's service.
- The filing contains no financial results, guidance, or operational metrics.
03—Questions
Frequently Asked Questions
When does Dr. Gilliland's retirement from the Board take effect?
His retirement is effective December 31, 2025. He notified the Board of his decision on December 5, 2025.
Which committees did Dr. Gilliland serve on?
According to the press release in Exhibit 99.1, he served on the Audit Committee and the Quality and Compliance Committee.
Does this filing report any financial impact?
No. The filing addresses only a board departure and does not include financial results, guidance, or financial impact figures.
Did the company name a replacement director?
The filing does not state a successor or any new director appointment.
What is Dr. Gilliland's background?
He has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center since January 2020. Earlier, he was inaugural Vice Dean and Vice President for Precision Medicine at the University of Pennsylvania Perelman School of Medicine and Senior Vice President of Merck Research Laboratories and Oncology Franchise Head, and he was on the faculty at Harvard Medical School for nearly 20 years.
04—Continue